{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:03:24Z","timestamp":1762459404462},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10354-016-0472-z","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T09:14:50Z","timestamp":1467710090000},"page":"58-65","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pyoderma gangrenosum\u2014a novel approach?"],"prefix":"10.1007","volume":"167","author":[{"given":"Anastasia Atanasova","family":"Chokoeva","sequence":"first","affiliation":[]},{"given":"Jos\u00e9 Carlos","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Wollina","sequence":"additional","affiliation":[]},{"given":"Georgi","family":"Tchernev","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"issue":"5","key":"472_CR1","first-page":"587","volume":"149","author":"E Cozzani","year":"2014","unstructured":"Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014;149(5):587\u2013600.","journal-title":"G Ital Dermatol Venereol"},{"key":"472_CR2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10354-014-0285-x","volume":"164","author":"U Wollina","year":"2014","unstructured":"Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164:263.","journal-title":"Wien Med Wochenschr"},{"key":"472_CR3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/CCID.S61202","volume":"8","author":"\u0410 Gameiro","year":"2015","unstructured":"Gameiro \u0410, Pereira N, Cardoso JC, Margarida Gon\u00e7alo M. Pyoderma gangrenosum: challenges and solutions. Clin Cosmet Investig Dermatol. 2015;8:285\u201393.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"472_CR4","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","volume":"58","author":"F Arg\u00fcelles-Arias","year":"2013","unstructured":"Arg\u00fcelles-Arias F, Castro-Laria L, Lobat\u00f3n T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, Soto-Escribano P, Calvo-Moya M, Ginard-Vicens D, Chaparro-S\u00e1nchez M, Hern\u00e1ndez-Dur\u00e1n M, Castro-Senosiain B, Fern\u00e1ndez-Villaverde A, Garc\u00eda-S\u00e1nchez V, Dom\u00ednguez-Mu\u00f1oz E, Caunedo-\u00c1lvarez A, Herrer\u00edas-Guti\u00e9rrez JM. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949\u201354.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"472_CR5","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/jid.2014.76","volume":"134","author":"HD Beer","year":"2014","unstructured":"Beer HD, Contassot E, French LE. The inflammasomes in autoinflammatory diseases with skin involvement. J\u00a0Invest Dermatol. 2014;134(7):1805\u201310.","journal-title":"J Invest Dermatol"},{"key":"472_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00128071-200203030-00002","volume":"3","author":"U Wollina","year":"2002","unstructured":"Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149\u201358.","journal-title":"Am J Clin Dermatol"},{"issue":"6\u20137","key":"472_CR7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.annder.2012.03.012","volume":"139","author":"D Lipsker","year":"2012","unstructured":"Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139(6\u20137):459\u201367.","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"472_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","volume":"66","author":"M Braun-Falco","year":"2012","unstructured":"Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka TJ. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) \u2013 a new autoinflammatory syndrome distinct from PAPA syndrome. Am Acad Dermatol. 2012;66(3):409\u201315.","journal-title":"Am Acad Dermatol"},{"issue":"14","key":"472_CR9","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"A Charles","year":"2011","unstructured":"Charles A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720\u201332.","journal-title":"Blood"},{"key":"472_CR10","doi-asserted-by":"crossref","first-page":"e27742","DOI":"10.4161\/rdis.27742","volume":"2","author":"JR Lukens","year":"2014","unstructured":"Lukens JR, Kanneganti TD. SHP-1 and IL-1\u03b1 conspire to provoke neutrophilic dermatoses. Rare Dis. 2014;2:e27742.","journal-title":"Rare Dis"},{"issue":"13","key":"472_CR11","first-page":"00089","volume":"pii: S1044-5323","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, Meer JW van der. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;pii: S1044-5323(13):00089\u201300084.","journal-title":"Semin Immunol"},{"issue":"1","key":"472_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1189\/jlb.1110616","volume":"90","author":"TA Doherty","year":"2011","unstructured":"Doherty TA, Brydges SD, Hoffman HM. Autoinflammation: translating mechanism to therapy. J\u00a0Leukoc Biol. 2011;90(1):37\u201347.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"472_CR13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","volume":"23","author":"T Jaeger","year":"2013","unstructured":"Jaeger T, Andres C, Grosber M, Zirbs M, Hein R, Ring J, Traidl-Hoffmann C. Pyoderma gangrenosum and concomitant hidradenitis suppurativa \u2013 rapid response to canakinumab (anti-IL-1b). Eur J Dermatol. 2013;23(3):408\u201310.","journal-title":"Eur J Dermatol"},{"key":"472_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ncprheum0681","volume":"4","author":"LD Church","year":"2008","unstructured":"Church LD, Cook GP. Michael F McDermott. Primer: inflammasomes and interleukin 1 bold beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008;4:34\u201342.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"472_CR15","first-page":"16","volume":"65","author":"WP Arend","year":"2002","unstructured":"Arend WP. The mode of action of cytokine inhibitors. J\u00a0Rheumatol Suppl. 2002;65:16\u201321.","journal-title":"J Rheumatol Suppl"},{"issue":"8","key":"472_CR16","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, Meer JWM van der. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"472_CR17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/labinvest.3780064","volume":"80","author":"M Oka","year":"2000","unstructured":"Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80(4):595\u2013604.","journal-title":"Lab Invest"},{"issue":"4","key":"472_CR18","first-page":"E1","volume":"92","author":"E Rallis","year":"2013","unstructured":"Rallis E, Koumantaki-Mathioudaki E, Tsiatoura A, Stavropoulos P, Katsambas A. Pyoderma gangrenosum and tumor necrosis factor \u03b1 agents. Cutis. 2013;92(4):E1\u20132.","journal-title":"Cutis"},{"key":"472_CR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.cdd.4402034","volume":"14","author":"BA Callus","year":"2007","unstructured":"Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ. 2007;14:73\u20138.","journal-title":"Cell Death Differ"},{"issue":"2","key":"472_CR20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12998\/wjcc.v1.i2.74","volume":"1","author":"M Zippi","year":"2013","unstructured":"Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases. 2013;1(2):74\u20138.","journal-title":"World J Clin Cases"},{"key":"472_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/09546631003797106","volume":"22","author":"MM Kleinpenning","year":"2011","unstructured":"Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J\u00a0Dermatolog Treat. 2011;22:261\u20135.","journal-title":"J Dermatolog Treat"},{"key":"472_CR22","first-page":"56","volume":"7","author":"G Tchernev","year":"2005","unstructured":"Tchernev G, Trebing D, G\u00f6ring H\u2011D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn\u2019s disease \u2013 the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56\u201360.","journal-title":"Bulg J Hepatogastroenterol"},{"key":"472_CR23","first-page":"930","volume":"137","author":"MH Tan","year":"2001","unstructured":"Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137:930\u20133.","journal-title":"Arch Dermatol"},{"issue":"1","key":"472_CR24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.crohns.2013.06.003","volume":"8","author":"N Teich","year":"2014","unstructured":"Teich N, Klugmann T. Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis. J\u00a0Crohns Colitis. 2014;8(1):85\u20136.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"472_CR25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s10227-005-0110-7","volume":"9","author":"AF Alexis","year":"2005","unstructured":"Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-\u03b1 therapies. J Cutan Med Surg. 2005;9(6):296\u2013302.","journal-title":"J Cutan Med Surg"},{"key":"472_CR26","doi-asserted-by":"crossref","first-page":"939847","DOI":"10.1155\/2013\/939847","volume":"2013","author":"A Vitale","year":"2013","unstructured":"Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm. 2013;2013:939847.","journal-title":"Mediat Inflamm"},{"key":"472_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Sch\u00f6nlebe J, K\u00f6stler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1\u201314.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"472_CR28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.taap.2009.06.013","volume":"240","author":"TL Chen","year":"2009","unstructured":"Chen TL, Chang CC, Lin YL, Ueng YF, Chen RM. Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells. Toxicol Appl Pharmacol. 2009;240(1):15\u201325.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"472_CR29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.taap.2007.11.027","volume":"228","author":"GJ Wu","year":"2008","unstructured":"Wu GJ, Chen TL, Ueng YF, Chen RM. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4\u2011mediated c\u2011Jun N\u2011terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol. 2008;228(1):105\u201313.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"472_CR30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488412803305821","volume":"7","author":"N Pazyar","year":"2012","unstructured":"Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7(4):271\u20135.","journal-title":"Curr Clin Pharmacol"},{"issue":"5","key":"472_CR31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161(5):1199\u2013201.","journal-title":"Br J Dermatol"},{"issue":"2","key":"472_CR32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/2013.jamadermatol.717","volume":"149","author":"A Geusau","year":"2013","unstructured":"Geusau A, Mothes-Luksch N, Nahavandi H, Pickl WF, Wise CA, Pourpak Z, Ponweiser E, Eckhart L, Sunder-Plassmann R. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209\u201315.","journal-title":"JAMA Dermatol"},{"key":"472_CR33","doi-asserted-by":"crossref","first-page":"616973","DOI":"10.1155\/2014\/616973","volume":"2014","author":"M G\u00f6n\u00fcl","year":"2014","unstructured":"G\u00f6n\u00fcl M, Cevirgen Cemil B, Keseroglu HO, Kaya Akis H. New Described Dermatological Disorders. Biomed Res Int. 2014;2014:616973.","journal-title":"Biomed Res Int"},{"issue":"8","key":"472_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/RHU.0b013e318278b84c","volume":"18","author":"V Bruzzese","year":"2012","unstructured":"Bruzzese V. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor \u03b1 therapy. J Clin Rheumatol. 2012;18(8):413\u20135.","journal-title":"J Clin Rheumatol"},{"key":"472_CR35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0733-8635(01)00029-8","volume":"20","author":"FC Powell","year":"2002","unstructured":"Powell FC, O\u2019Kane M. Management of pyoderma gangrenosum. Dermatol Clin. 2002;20:347\u201355.","journal-title":"Dermatol Clin"},{"key":"472_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-2-19","volume":"2","author":"U Wollina","year":"2007","unstructured":"Wollina U. Pyoderma gangrenosum \u2013 a review. Orphanet J Rare Dis. 2007;2:19.","journal-title":"Orphanet J Rare Dis"},{"key":"472_CR37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(96)90428-4","volume":"34","author":"FC Powell","year":"1996","unstructured":"Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: Classification and management. J\u00a0Am Acad Dermatol. 1996;34:395\u2013409.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"472_CR38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1089\/wound.2011.0339","volume":"1","author":"H Goodarzi","year":"2012","unstructured":"Goodarzi H, Sivamani RK, Garcia MS, Wehrli LN, Craven H, Ono Y, Maverakis E. Effective Strategies for the Management of Pyoderma Gangrenosum. Adv Wound Care (New Rochelle). 2012;1(5):194\u20139.","journal-title":"Adv Wound Care (New Rochelle)"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-016-0472-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0472-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-016-0472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T12:04:13Z","timestamp":1600862653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-016-0472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":38,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["472"],"URL":"https:\/\/doi.org\/10.1007\/s10354-016-0472-z","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]}}}